clinical trial · NCT06898957
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
Amgen·phase1·active not recruiting·n = 200
Small Cell Lung CancerYL201TarlatamabAtezolizumabDurvalumab
brief summary
The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.
started
May 16, 2025
primary completion
Jun 23, 2031
completion
Jun 23, 2031
last updated
Apr 22, 2026
official title
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With YL201 With or Without Anti-PD-L1 in Subjects With Extensive Stage Small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol